Abcam in Glassdoor’s top 5 ‘best places to work in the UK’ for second consecutive year
Abcam, a global innovator empowering life science researchers with high-quality biological reagents and tools critical to research, drug discovery and diagnostics, has received the Employees’ Choice Award 2022, recognising Abcam in Glassdoor’s Best Places to Work in the UK. Abcam is the first biotech company to be ranked in the top five for two years in a row1.
Abcam completes acquisition of BioVision
Abcam plc (AIM LSE: ABC; Nasdaq: ABCM), a global leader in the supply of life science research tools, today announces that is has completed its acquisition of BioVision Inc from Boai NKY Medical Holdings Ltd for total consideration of $340m.
Abcam to acquire BioVision for $340 million
Abcam plc (AIM LSE: ABC; Nasdaq: ABCM), a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire BioVision, Inc, a wholly owned subsidiary of Boai NKY Medical Holdings Ltd (NKY), for $340 million.
Abcam opens new US facility in Boston, MA
Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences reagents and tools, announces the opening of a major new site in Waltham, MA.
Abcam moves to new purpose-built global headquarters
Abcam, a global innovator in life science reagents and tools, is pleased to announce its move to new state-of-the-art global headquarters, Discovery Drive, on the Cambridge Biomedical Campus (CBC), UK, a leading hub of healthcare, science and medical research.
Abcam reports continued strong sales growth, ahead of underlying market rates
Abcam plc (AIM: ABC) a global leader in the supply of life science research tools, is pleased to announce its interim results for the six-month period ended 31 December 2017*.
Abcam signs exclusive licence agreement with Roche
Abcam, a global leader in the supply of life science research tools, is pleased to announce that it has entered into a definitive licence agreement with Roche.
Abcam presents at the 36th annual JP Morgan Healthcare Conference
Abcam plc, a global leader in the supply of life science research tools, announces that Alan Hirzel, Chief Executive Officer, will present at the 36th Annual JP Morgan Healthcare Conference in San Francisco, California, tomorrow (Wednesday, January 10, 2018), at 16:30 Pacific Standard Time.
Abcam continues to deliver double-digit revenue growth
Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, announces an unaudited trading update ahead of its results for the six months ended 31 December 2017.(1)
Abcam Chairman to step down
Abcam plc, a global leader in the supply of life science research tools announces that its Chairman, Murray Hennessy, has informed the Board that he has accepted a CEO role and will therefore relinquish his Non-Executive Chairman position and step down from the Board following the AGM in November 2017.
Abcam reports double-digit earnings growth, enabling investment for sustained future growth
Abcam plc, a global leader in the supply of life science tools, is pleased to announce its preliminary results for the year ended 30 June 2017*.
Abcam delivers over 10% sales growth
Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, announces the following unaudited trading update for the year ended 30 June 2017 ahead of the publication of its financial results on 11 September 2017.
Ground breaking takes place on Abcam Plc global headquarters at Cambridge Biomedical Campus
Joint developers of Cambridge Biomedical Campus (CBC), Liberty Property Trust and Countryside Properties have held a ground breaking ceremony with Abcam Plc to commemorate the start of construction of Abcam’s new 100,000 sq ft global headquarters.
Abcam makes final performance-based AxioMx milestone payment
Abcam plc, a global leader in the supply of life science research tools, is delighted to announce that further to its acquisition of AxioMx, Inc. in November 2015 the final performance-related milestones have been successfully achieved.
Abcam revenues continue to grow
Abcam plc, a global leader in the supply of life science research tools, announces the following unaudited trading update ahead of its results for the six months ended 31 December 2016. (1)
Abcam commits to lease a new facility on the Cambridge Biomedical Campus
Abcam plc, a global leader in the supply of life science research tools, announces that it has committed to the lease of a new facility for its global headquarters at the expanding Biomedical Campus in Cambridge, UK, subject to the grant of full planning approval.
Abcam reports strong revenue performance, enabling investment for future growth
Abcam plc, a global leader in the supply of life science research tools, is pleased to announce its preliminary results for the year ended 30 June 2016 (1).
Abcam delivers close to 16% sales growth, while investing for the future
Abcam plc, a global leader in the supply of life science research tools, has issued an update for the year ended 30 June 2016, ahead of the publication of its financial results on 12 September 2016.
Abcam appoints Gavin Wood, former Affymetrix executive, as Chief Financial Officer
Abcam plc, a global leader in the supply of life science research tools, announces that Gavin Wood, former Executive Vice President (EVP) and Chief Financial Officer (CFO) of Affymetrix Inc., is to succeed Jeff Iliffe as Abcam's CFO.
Abcam delivers sustained double digit revenue growth while investing in the future
Abcam plc, a global leader in the supply of life science research tools, announces its interim results for the six-month period ended 31 December 2015 [1].
Jim Warwick steps down from Abcam Board
Abcam plc, a global leader in the supply of life science research tools, announces that after 15 years at Abcam, Jim Warwick has today served notice of his intention to retire from Abcam and step down from the Board by the end of 2016.
Abcam maintains momentum with market beating sales growth
Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, has announced a trading update ahead of its results for the six months ended 31 December 2015 [1].
Abcam acquires AxioMx to access new growth opportunities and extend antibody leadership
Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire the entire issued share capital of AxioMx, Inc. on a cash-free/debt-free basis for $20m upfront with further performance-based payments totalling $25m.
Abcam announces strong start to the new financial year
Abcam plc, a global leader in the supply of life science research tools, is holding its Annual General Meeting this morning.
Abcam’s new anti-PD-L1 antibody enables deeper insights into cancer immunology research
Abcam plc, a global leader in the supply of life sciences research tools, has announced the launch of its anti-PD-L1 primary antibody (clone 28-8). Produced using Abcam’s RabMAb® recombinant monoclonal antibody technology, the clone offers highly specific and reproducible antigen recognition to a checkpoint inhibitor critical to current cancer immunology research.